GSK’s Share Price Offers Attractive Risk Reward, Jefferies Says
GSK is expected to guide for at least low single-digit EPS growth for 2024 and settle the Zantac litigation case within the coming months, Jefferies said, raising its rating on the stock to buy from hold and lifting its target price to 1,900 pence from 1,550 pence. Continue reading